Article2013 ACM Conference on Bioinformatics, Computational Biology and Biomedical Informatics : ACM - BCB 2013 : Washington, D.C., U.S.A., September 22 - 25, 2013. ACM Conference on Bioinformatics, Computational Biology and Biomedical Informa...
Classification of Alzheimer Diagnosis from ADNI Plasma Biomarker Data.
Article in 2013 ACM Conference on Bioinformatics, Computational Biology and Biomedical Informatics : ACM - BCB 2013 : Washington, D.C., U.S.A., September 22 - 25, 2013. ACM Conference on Bioinformatics, Computational Biology and Biomedical Informa.... The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline.Journal of Alzheimer's disease : JAD · 2025Article
- Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.JAMA network open · 2023Article
- Medical Plants and Nutraceuticals for Amyloid-β Fibrillation Inhibition.Journal of Alzheimer's disease reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Research into modeling the progression of Alzheimer's disease (AD) has made recent progress in identifying plasma proteomic biomarkers to identify the disease at the pre-clinical stage. In contrast with cerebral spinal fluid (CSF) biomarkers and PET imaging, plasma biomarker diagnoses have the advantage of being cost-effective and minimally invasive, thereby improving our understanding of AD and hopefully leading to early interventions as research into this subject advances. The Alzheimer's Disease Neuroimaging Initiative* (ADNI) has collected data on 190 plasma analytes from individuals diagnosed with AD as well subjects with mild cognitive impairment and cognitively normal (CN) controls. We propose an approach to classify subjects as AD or CN via an ensemble of classifiers trained and validated on ADNI data. Classifier performance is enhanced by an augmentation of a selective biomarker feature space with principal components obtained from the entire set of biomarkers. This procedure yields accuracy of 89% and area under the ROC curve of 94%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.